Regions of high level gain or amplification encompassed key cancer genes such as MYCN (2p), the EVI1/MDS1 cluster (3q), FGFR1 (8p), OCT4 and MYC (8q) and KRAS (12p) of which a number are potential therapeutic targets. This evidence concerns the gene KRAS and cancer.